Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Latuda

- PMLiVE

Takeda announces EC approval for Adcetris combination in Hodgkin lymphoma

The ADC has been approved alongside doxorubicin, vinblastine and dacarbazine

- PMLiVE

Takeda announces CHMP recommendation for Adcetris in Hodgkin lymphoma

The ADC has been recommended with doxorubicin, vinblastine and dacarbazine

- PMLiVE

Takeda announces positive phase 2b results for TAK-279 in psoriatic arthritis

Approximately 10 million people worldwide are affected by the inflammatory disease

- PMLiVE

Takeda and F-star announce immunotherapy partnership worth over $1bn

Both companies will research and develop antibodies for new immuno-oncology targets

EU flag

EMA addresses considerations for single-arm trials as pivotal evidence in regulatory filings

The reflection paper offers suggestions on trial design and strategies for minimising bias

- PMLiVE

Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis

Plaque psoriasis accounts for around 80-90% of the 125 million psoriasis cases worldwide

- PMLiVE

Takeda’s dengue vaccine receives MHRA approval for those aged four years and older

Around 3.9 billion people globally are currently at risk of dengue, a mosquito-borne viral disease

- PMLiVE

Takeda’s all-oral multiple myeloma triplet therapy recommended by NICE

Ninlaro with lenalidomide and dexamethasone improved clinical outcomes

- PMLiVE

Takeda therapy shows promise in rare blood clotting disorder

Phase 3 results show the enzyme replacement therapy reduced thrombocytopenia events by 60%

- PMLiVE

Takeda to acquire Nimbus’ TYK2 inhibitor in deal worth $6bn

NDI-034858 is under evaluation for the treatment of multiple autoimmune diseases

- PMLiVE

Takeda’s dengue vaccine receives EC approval

The decision follows a positive recommendation for Qdenga from the CHMP in October

- PMLiVE

Takeda’s Exkivity receives NICE recommendation for rare form of lung cancer

Patients with EGFR Exon20ins+ NSCLC make up approximately 2% of NSCLC cases

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links